Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Rhumbline Advisers lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 410,508 shares of the biopharmaceutical company’s stock after purchasing an additional 5,833 shares during the period. Rhumbline Advisers owned 0.32% of Halozyme Therapeutics worth $19,626,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Louisiana State Employees Retirement System raised its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 200 shares in the last quarter. Verdence Capital Advisors LLC raised its stake in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares in the last quarter. Diversify Advisory Services LLC raised its stake in shares of Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 418 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its stake in shares of Halozyme Therapeutics by 7.7% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 507 shares in the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Halozyme Therapeutics by 0.5% during the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock worth $6,367,000 after acquiring an additional 561 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $57.44 on Friday. The firm has a market cap of $7.31 billion, a price-to-earnings ratio of 16.75, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $36.61 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock’s fifty day moving average price is $53.26 and its two-hundred day moving average price is $54.58.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 165.13% and a net margin of 43.74%. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.72 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright boosted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday. Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday. Finally, Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.